LUCD
Lucid Diagnostics Inc. [LUCD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LUCD Stock Summary
Top 10 Correlated ETFs
LUCD
Top 10 Correlated Stocks
LUCD
In the News
LUCD Financial details
Company Rating
-
Market Cap
39.03M
Income
-2.02B
Revenue
2.43M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
-0.03
Forward P/E
-
PEG
-0
P/S
44.07
P/B
24.24
P/C
-
P/FCF
-2.42
Quick Ratio
0.8
Current Ratio
0.9
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-49.18
EPS next Y
-
EPS next Q
-
EPS this Y
-18.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
32.82%
EPS Q/Q
-23.53%
-
-
-
-
SMA20
47.37%
SMA50
79.49%
SMA100
72.84%
Inst Own
-
Inst Trans
-
ROA
-6075%
ROE
-12318%
ROC
-17.2%
Gross Margin
-309%
Oper. Margin
-3464%
Profit Margin
-134639%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.7811-1.85
52W High
-
52W Low
-
RSI
58.6
Rel Volume
2.21
Avg Volume
151.17K
Volume
333.56K
Perf Week
-2.8%
Perf Month
64.11%
Perf Quarter
66.35%
Perf Half Y
74.27%
-
-
-
-
Beta
1.625
-
-
Volatility
0.07%, 0.24%
Prev Close
0%
Price
1.39
Change
-4.14%
Company Profile
- Volume Average 151.17K
- Market Capitalization 39.03M
- Employee 70
- CEO Dr. Lishan Aklog M.D.
- Headquarters New York,NY,US
- IPO Date 2021-10-14
-
Website
https://www.luciddx.com 
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
